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Abstract
Many psychotropics prescribed to children are unlicensed or off-label. This article uses the two
most prescribed psychotropics (MPH and SSRIs) to illustrate various concerns about their impact
on youth. Many mental illnesses begin in childhood or early adulthood, warranting a treatment of
some kind. However, commentators have argued that prescribing is influenced by five myths: (1)
children are little adults; (2) children have no reason to develop depression or anxiety; (3)
psychiatric disorders are the same across adults and children; (3) children can be prescribed lower
doses of the same drug; (5) drugs are preferable to alternative treatments and are more successful.
Several lines of evidence suggest that these are incorrect assumptions. We update readers with
recent research in relation to these myths, concluding that researchers should clarify child/adult
differences for psychotropics, attend to the growth of "cosmetic" use of psychotropics in children
and adolescents, and address concerns about the diagnostic validity of mental illness in the current
DSM classification system.
Background
At the level of individual use, both legal (alcohol,
tobacco) and illegal (amphetamine, cannabis, and
cocaine) psychotropics have a well-documented, short-
and long-term impact on young people's health. Psycho-
tropics include antidepressants, stimulants, antipsychot-
ics, benzodiazepines, and other anxiolytics [1]. This
article considers prescribed psychotropics.
Many psychotropics prescribed to children are unlicensed
or off-label, meaning that they are used for purposes other
than for which they are officially approved [2]. However,
little is known about their long-term impact. The dramatic
rise in prescriptions over the last ten years has raised con-
cern about the potential for harm [3,4].
This article uses the two most prescribed psychotropics as
examples to illustrate the concern about their impact.
Methylphenidate (MPH, e.g., Ritalin) and selective serot-
onin reuptake inhibitors (SSRIs, e.g., Prozac, Seroxat) are
prescribed most often [5]. Yet, very little research into
their safety and efficacy with children and young people
exists. Clinicians may therefore prescribe off-label in the
absence of reliable data. Fortunately, clear reasons for the
lack of data exist, and the situation is improving in several
ways.
Knowns and unknowns
Psychotropics can form an important part of treatment
intervention for certain mental illnesses. Successful treat-
ment of psychological disorders at a young age has the
potential to reduce adult morbidity [6]. Many mental ill-
nesses begin in childhood or early adulthood, warranting
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proven effective. For example, stimulants can treat atten-
tion deficit hyperactivity disorder (ADHD). SSRIs are
approved for treatment of obsessive-compulsive disorder
[7], depression [8] and anxiety disorders in children. A
recent clinical trial by the National Institute for Health
and Clinical Excellence in the United Kingdom showed
fluoxetine (with or without cognitive behavioral therapy,
CBT) "to be the only selective serotonin reuptake inhibi-
tor that is more effective than placebo in treating teenage
patients with depression" [cited in 2, p. 1464]. These
drugs may not be appropriate in all circumstances, how-
ever. The FDA approved Ritalin only for treatment of
ADHD in children six years or higher [3]. Some antide-
pressants (sertraline and fluvoxamine) have been
approved for OCD but not depression in school-age chil-
dren [[5] , p. 983]. A warning was introduced by the FDA
and the European Medicines Agency in 2003–2004 about
the increased suicide risk of initiating SSRI treatment with
antidepressants in children and adolescents, which has
lowered the number of prescriptions made in recent years
[9]. Gibbons et al. suggest that this may explain increasing
suicide rates, because it results in untreated depression.
This is clearly an important area for future research and "a
major priority in designing national suicide prevention
strategies" (p. 1361). Although a meta analysis showed no
statistically significant differences between SSRI and con-
trol groups, [10], a more recent study found suicidal
events occurred at a rate of 4.7% in the "SSRI plus CBT"
condition, and 9.2% in "SSRI alone" condition (signifi-
cant at p = 0.0402 vs. placebo), compared to 2.7% in the
"placebo" condition [11]. However, an alternative expla-
nation for the SSRI-suicide association is that patients
"acquire energy to act on continued suicidality and/or
may gain cognitive clarity to act on their suicidal inten-
tions" [[12] , p. 84]. Joiner et al. argue that the increased
"energy" after remission hypothesis is more likely due to
incomplete remission in patients who were more
depressed, from the outset.
Recent trends
Despite the narrow range of situations in which prescrip-
tions can be supported by safety and efficacy data, drugs
are prescribed for an increasing range of disorders and for
increasingly younger patients. We have seen a large
increase in prescriptions for antipsychotic drug use, not
accompanied by any parallel rise in the prevalence of psy-
chotic illnesses [1,2]. The UK has had the highest percent-
age increase (68 percent), with Germany the lowest (13
percent) [1]. The ten-year prevalence of MPH prescrip-
tions increased by up to 3.7 times for Medicaid patients
and 7.2 times for HMO patients [Safer, Zito & Fine, 1996,
cited in 3]. In the UK, MPH prescriptions increase from
2000 in 1990 to 350 000 in 2004 [[13], p. 64]. Trends by
age have also changed, with 10- to 14-year-olds now most
often treated with stimulants. This could suggest "a
lengthening of the duration of treatment" [2]. For SSRIs,
gendered patterns of prescribing have also changed. His-
torically, males have tended to receive more stimulants,
"but the sex gap has narrowed, and SSRI prevalence by sex
was approximately equal between males and females in
1998" [[14], p. 564]. None of these trends parallel equiv-
alent changes in the prevalence of the mental disorders
the psychotropics are designed to treat, which suggests a
discrepancy between prescribing practice and disorder
prevalence [see [14-16]].
Up to 60 percent of drug prescriptions in the U.S. are off-
label, a sizeable portion of which are written for children
and adolescents [17]. The principal reason why prescrip-
tions are written off-label is the lack of research (discussed
below). Clinicians are justified in prescribing off-label
because they have to balance beneficence (using profes-
sional judgement to treat and enhance quality of life) with
nonmaleficence (protecting from unsafe or ineffective treat-
ments). In the absence of research into psychotropics for
children and young people, little choice may exist, other
than to use treatments with proven effectiveness for
adults. Wiznitzer & Findling [18] discussed five popular
myths in relation to psychotropics and youth. Here, we
use these myths to update readers with recent research
findings, debates and practice guidelines.
1. Children are little adults
The putative biological substrate for psychiatric disorders
might vary as a function of age. The therapeutic effect,
potential adverse events, and interactions with other
drugs, can therefore vary with age. The brain evolves con-
tinues to evolve throughout adolescence [18], providing
what might be termed a moving target for clinicians and
researchers. The underlying biological substrate for
depression, for example, might change, even if the psy-
chological construct that defines depression does not [19]
and "there is inadequate research on the neurodevelop-
mental consequences of recurrent or chronic episodes of
mood disorder during different periods of brain develop-
ment" at the clinical level [[19] , p.964]. This may explain
"the lack of efficacy and poor side-effect profile for tricy-
clic antidepressants" [[20], p. 1341]. These older drugs
have long been discouraged for use on the young. More
recently, SSRIs discouraged for use as treatments for
depressed children and adolescents [20]. This change was
informed partly by the observation of increased suicide
risk among adolescents taking SSRIs, discussed in more
detail below [9,10,21]. Leeder argues that "infants, chil-
dren, and adolescents simply cannot be treated as 'small
adults.' Rather, they represent distinct subpopulations,
each with their own unique characteristics, and, thus, the
response to drug therapy from birth to adolescence and
adulthood is a function of developmental processes thatPage 2 of 10
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their pharmacologic targets" [[22], p. 765].
The first myth, that children are little adults, is particularly
important, given recent research into the developing
brain. The developing brain is anatomically vulnerable.
The significant developmental differences between adults
and children have implications for pharmacological
effects [23]. As the brain develops, cellular events are "pro-
grammed" to unfold in a particular sequence. Disturbance
of this normal process of self-assembly is a central mech-
anism in many disease processes. Neurons play a different
role in the developing brain than in the adult brain. Car-
rey [23] argues this could affect response to psychophar-
macological interventions. Long-term damage is possible,
and psychoactive drugs could interact with brain develop-
ment. The long-term safety of psychotropic agents for the
brain is not known, and safety/efficacy studies for pre-
schoolers are few and far between [5,24]. It is possible that
stimulants such as Ritalin can desensitize the brain, lead-
ing to later substance abuse [5]. Phenobarbital can cause
permanent negative effects on cognition [17]. SSRIs have
been linked to irritability, shivering, agitation, hypotonia,
and pulmonary hypertension in newborns [17,25].
Why is there so little research into the safety and efficacy
of psychotropics for children and young people? Accord-
ing to Spetie & Arnold [17], although controlled trials
have been conducted for psychiatric disorders in children
[for examples, see [4]], these were historically more diffi-
cult to conduct. Children are defined as a vulnerable pop-
ulation, and it can be difficult to obtain informed consent
from minors or their parents. Researchers have therefore
been historically reluctant to enrol children in psychop-
harmacological research, "leading to a scarcity of data on
the effectiveness, safety and pharmacokinetics of psycho-
active agents" for preschoolers [[17], p. 16]. This reluc-
tance has arguably made children more vulnerable,
because little safety data exists for clinicians to refer to.
Clinicians may not see it as appropriate to withhold a
potentially useful treatment simply because it has not
been approved for children. This situation is changing
[see [4]]:
• From 1994, the FDA has required pharmaceutical com-
panies to test certain drugs at pre-market stage for chil-
dren. Prior to this, drugs were simply labelled with "safety
and efficacy not established for children." There now
exists a financial incentive to conduct pediatric studies,
such as the six-month patent extension for fluoxetine [see
[17]].
• From 1996, Pediatric Pharmacology Research Units
(PPRUs) set up by the National Institute of Child Health
and Human Development have helped limited efficacy
and pharmacokinetic studies take place [4].
• From 1997, the Research Units on Pediatric Psychophar-
macology (RUPPs) produced pediatric data on the effi-
cacy of several psychotropics, funded my the National
Institute of Mental Health (NIMH).
• From 1997, pharmaceutical companies were granted a
"6-month extension of drug exclusivity...in return for spe-
cific pediatric studies" by the US congress [see [4]].
• In 2002, this was extended to 2008 under the Best Phar-
maceuticals for Children [4].
• In 2003, pediatric studies were now required "as part of
the premarketing development of drugs" [[4], p. 6].
There does, however, remain a set of factors which make
ethical approval more difficult to obtain. For example,
informed consent is more difficult to achieve in the pres-
ence of cognitive immaturity, parents' protective roles
may be influenced by the emotional state of the child,
coercion may exist from parents or indirectly via high
financial reimbursements, placebos (discussed below)
may need to be administered "to determine effective treat-
ment when no or poor evidence base" [[17], p. 16].
A second reason why there is comparatively little research
is that it is difficult to obtain ethical approval specifically
to study the mechanistic effects of drugs. Ethical approval
is easier to obtain if the study offers children a direct ben-
efit [24]. Mechanistic studies are highly informative, but
do not necessarily offer the individual patient any direct
benefit [24]. Third, and related, is that children may be
assigned to a dummy treatment group where no real med-
ication is provided. This improves the reliability of clinical
trials because placebo effects are known to be quite strong
[17]. A placebo effect occurs "When the effects of a drug
are temporally correlated with its administration and can-
not be attributed to its chemical properties – its pharma-
codynamic activity – they are known as placebo effects"
[[26], p. 282]. Patients, families, and clinicians can all
believe that a patient's condition is improving when, in
fact, no medication was administered. This is why the
"best" clinical trials are deemed to be randomized, pla-
cebo-controlled trials. Researchers disagree on whether a
placebo condition offers children any direct benefit,
because the findings are mixed, depend on the condition,
and raise ethical concerns [7,10,24,27]. However, they
generally recognize that placebo effects should be
included in research designs [28]. On the one hand, they
still receive a "non-specific, repeated clinical contact"
which has demonstrated benefits [[24], p. 89]. On the
other hand, they are not receiving any potentially helpfulPage 3 of 10
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conditions are more justifiable for children, because there
is so little safety/efficacy research available. Sometimes
the placebo effect is so strong it cannot be considered a
true absence of treatment [see [28]]. When the efficacy of
a drug is known or demonstrated, the situation is more
complicated. Many consider it unethical to withhold
treatment from a group of children when we know the
treatment works. Spetie & Arnold [17] cite "the notorious
case of the Tuskegee study, in which syphilitic patients
were left untreated, even after the discovery of penicillin"
[[17], p. 22]. It is considered ethical to stop placebo-con-
trolled trials if a strong effect of the drug becomes appar-
ent [29].
2. Children have no reason to develop depression or 
anxiety
The beliefs that mood disorders are rare before adulthood
and mood disturbance is a normal aspect of child and
adolescent development are misconceptions [30]. There is
a large and growing literature demonstrating the inci-
dence and prevalence of pediatric depression, anxiety, and
other mood disorders (e.g. mania, obsessive compulsive
disorder). Reviewing these rates, Hankin, Abramson, and
Siler [31] report that between 15 and 18 years of age, one-
year prevalence of depression increases from 3 percent to
18 percent. Depressed mood is reported by 25 to 40 per-
cent of adolescents, and researchers estimate "that 2–6%
of children and adolescents in the community suffer from
depression [20,32], p. 1341]." This implies the existence
of a critical period during which the risk of depression is
highest. Children are surrounded by life stressors, and
may not develop adequate coping mechanisms [18].
Moreover, the number of negative life events experienced
increases during middle to late adolescence. This may
offer a partial "explanation of why so many individuals
become depressed for the first time in adolescence [[31],
p. 624–625]." Evidence that self-reported depression cor-
responds with parent and teacher ratings provides validity
for the existence of this disorder in youth, despite its
"internalizing" nature [see [33]]. It is not widely agreed,
however, how data from multiple informants "should be
combined to yield diagnoses [[30], p. 1003]." Some of the
consequences of depressive disorders may reflect not only
impairment of the disorder, but may represent a core
symptom of the disorder itself. The phenomenology of
depressive disorders in children may change as a function
of age, which is discussed below.
Risk factors for child and adolescent depression
Children can develop mood disorders, and there are risk
factors. For example, negative cognitions (thought proc-
esses) about the self are predictive of depression in adults
and children [34]. Low self-esteem, negative self schemas
(representations of the self) and/or negative cognitions
"are hypothesized to play a role in the onset and mainte-
nance of depression" [[34], p. 371]. Schemas are "endur-
ing mental constructs [that] organize, guide, interpret,
and retrieve information about the self in memory [[35],
p. 216]." Depression may occur when the self is dimin-
ished in some way, by "a loss, failure, depletion, evidence
of undesirability or inefficacy [[36], p. 218]."
Perceived control over life events is a second risk factor for
depression. Although only limited research is available,
studies to date suggest children with an external locus of
control, or a general perception of low control, are more
likely to develop depression [34]. In the authors' own
study, having a low academic grade interacted with the
presence of a generally negative attributional style; to pro-
duce negative affect and depressive symptoms for preado-
lescents. Some of these symptoms occurred before the
stressor itself, suggesting children anticipated the stressor
or a general tendency to experience these symptoms
existed. Those without negative cognitions were less likely
to develop depressive symptoms after receiving a lower
than expected grade. Students with positive cognitions
were protected against depressive symptoms, even among
those receiving lower than acceptable grades. These results
show that stressful life events in children can lead to
depression, particularly when moderated by negative cog-
nitions. Other researchers argue, however, that life events
are a stronger predictor than the "hopelessness as media-
tor" hypothesis. These events are stressors, which can pro-
voke learned helplessness and hopelessness in children.
Learned hopelessness refers to "the expectation that
highly desirable outcomes will not occur or that highly
aversive events will occur [[31], p. 608]." Depression is
more likely among those with stable, global and internal
cognitive processes ("negative beliefs regarding them-
selves, their future, or their situation [[31], p. 378]." Not
all individuals react in this negative way, suggesting that
"negative cognitions are a vulnerability factor that inter-
acts with negative life events to contribute to the onset
and maintenance of depression [[34], p. 370]." In the
revised version of the learned hopeless theory, the stable
and global aspects of these negative cognitions considered
to be more important than the internal dimension [31] -
negative beliefs that the event will always happen and will
happen in most situations. An empirical test of negative
cognitions versus life events in the onset of adolescent
depression found more support for stressful life events.
The importance of life events remained, regardless of
whether "stable + global + internal" or simply "stable +
global" styles were considered. The increase in stressful
life events during adolescence may correspond with and
partially explain the increase in the prevalence of depres-
sion.Page 4 of 10
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documented [30], with strong evidence for genetic contri-
butions to depression and other disorders. It is plausible
that reducing the incidence of depression in children and
adolescents "might be successful in preventing subse-
quent adverse role transitions and, indirectly through this
effect, might reduce the prevalence of mood disorders in
adulthood [[30], p. 1010]." Genetic factors are key deter-
minants of mood disorders, making it likely that the onset
and course of the disorder can be identified earlier than in
adulthood. However, researchers will need to consider
gene-environment interactions. The influence of parental
disorders on child disorders could be genetic, environ-
mental (e.g., parenting style), or both. The pathways are
difficult to discern because parental disorders are "part of
a complex cluster of risk factors [[30], p. 1007]." Parents'
behavior can create environments in which stressful life
events occur, making it difficult to disentangle the genetic
contribution from the environmental contribution.
3. Psychiatric disorders are the same across adults and 
children
Although the phenomenology of depression appears to be
similar in adolescents when compared to adults, key dif-
ferences in symptomatology exist [37]. The clinical picture
varies as a function of age. Younger children tend to show
"anxiety, somatic complaints, auditory hallucinations,
and behavioral problems", where older children and ado-
lescents tend to show "sleep and appetite changes, sui-
cidal ideation, and impairments of functioning" [[37], p.
8]. Features that would be considered consequences of
depression in older children and young adults (e.g.
declining school performance), might be considered a
symptom of the disorder itself, in younger children [37].
Kessler et al. [30] note the "important exception is that
irritability is included as a core symptom of depression
among children and adolescents, but not adults [[16], p.
1003]." They suggest that if irritability were included as a
component of depression for males, this might have the
additional side benefit of reducing gender differences in
rates of depression. Put differently, prevalence may be the
same, but men are more likely to present irritability as a
manifestation of their depression. Asecond way in which
disorders may differ between adults and children is the
extent to which symptom profiles should be considered
"clinically significant." Many studies apply the same diag-
nostic thresholds used for adults onto children. Thresh-
olds are designed to "employ explicit rules for assessing
syndromes in terms of frequency, duration, and impair-
ment [[30], p. 1003]." Yet there are "intriguing differences
in depression symptom profiles with age [[30], p. 1003].
Older children show decreases in self-esteem, somatic
symptoms, and agitation. Mania is a good example of
how diagnostic thresholds may need to adapt to different
age groups. A large proportion of children (5 to 11 per-
cent) show manic-like symptoms, but because these per-
sist only for a few hours or days, they do not meet the
formal, adult threshold for bipolar disorder. Euphoria
and irritability would need to persist for four or seven
days, for bipolar II and I, respectively. Furthermore, mood
disorders are often comorbid with other disorders, such as
anxiety, ADHD, or substance use [38]. The extent of
comorbidity may be different in adolescents than in
adults. Issues surrounding diagnosis may reflect problems
with the diagnosis of mood disorders themselves, rather
than adult/child differences. The Diagnostic and Statisti-
cal Manual of Mental Disorders (DSM) [39] places mood
disorders and substance use disorders on Axis I, but there
is considerable overlap with the personality disorders of
Axis II (discussed below). Furthermore, "DSM criteria are
not sufficiently explicit to provide clear guidelines regard-
ing a number of required classification distinctions, such
as "clinically significant" impairment and "marked" dis-
tress" [Angold et al. 1995, cited in 30, p. 1004]. Many
patients receive more than one disorder, leading to con-
cern about the validity of categorical approaches to mood
and personality disorders [38]. Kessler et al. [30] note that
children and adolescents with bipolar disorder almost
always have at least one other disorder. They argue that an
"admixture of manic, attention deficit, and hyperactive
symptoms [[30], p. 1007]" may in fact reflect diagnostic
confusion. The fact that the phenomenology of disorders
may change as a function of age, complicates DSM and
other classificatory schemes further. The definition, onset,
duration and impairment caused by the disorders may
have to be qualified with age-specific information, to
reach the moving target that constitutes the child's disor-
der. Measures designed to diagnose disorders would have
to take this into account, rather than simply adapting
measures designed for adults. The point that children are
not small adults (discussed above) applies to diagnosis, as
well as biological substrates. Ideally, age-sensitive meas-
ures would be adaptable for use in primary care settings.
Primary care is where most depression is diagnosed and
treated, and is the first point of contact for children with
disorders [37].
Adults and children also differ in the extent to which their
disorders are treated. In their review, Kessler et al. [30]
note that (1) the vast majority of depressed adolescents
seek help, (2) delays in help seeking are related to age, and
(3) the likelihood of receiving help has increased in recent
years. Research into patterns of help seeking is particularly
informative, because the consequences of untreated
depression are dangerous for young people. A "pileup of
cumulative adversity [[30], p. 1009]" from early mood
disorders can increase the likelihood of unfavorable social
outcomes, such as low education attainment, teenage
pregnancy, and secondary substance abuse. Unfortu-Page 5 of 10
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takes place. Externalizing symptoms, such as mania, are
easier for clinicians to identify, making internalizing dis-
orders more problematic. Early identification and inter-
vention may prevent future psychopathology. Kessler et
al. [30] note that, "Given that early-onset depression is
often preceded by one or more anxiety disorders, inter-
ventions aimed at childhood-onset primary anxiety might
be even more effective [[30], p. 1010]." Clearly, longitudi-
nal research into the symptoms, diagnostic validity, and
treatment options for children and adolescents would be
particularly valuable. Despite a paucity of research, suffi-
cient evidence indicates that psychological disorders are
not the same for adults and children.
4. Children can be prescribed a lower dose of the same 
drug
Evidence to support the claim that children can be pre-
scribed the same drugs as adults but at a lower dose is lim-
ited. Wiznitzer & Findling [18] note that
pharmacokinetic, pharmacodynamic, and response
effects change across different age ranges. Factors such as
metabolic rate can be taken into consideration when
administering doses of psychotropics, so that doses can be
adjusted depending on body weight. Age alone is not an
appropriate variable on which to adjust dosage. Age "is
the more dominant factor in the variability of drug action
in the infant and young child" but later in life, age and
body size diverge and dosage may need to be tailored to
weight [[26], p. 260]. Dosage options should be informed
by "scientifically-based investigation rather than weight
adjusted dosing extrapolated from adult data [[18], p.
1147]." Several side effects from SSRI use in children have
been described in the literature, including insomnia,
fatigue, abdominal discomfort, sleep problems, decreased
appetite, and excitement see [40]. Some of these effects are
temporary, and may depend on the length of treatment,
but "the long-term effects of these drugs on the develop-
ing nervous system is not known and needs to be weighed
against the potentially serious and noxious consequences
of no treatment and persistent symptoms [40]." Weintrob
et al. describe four children (aged 11 to 14) who showed
decreased growth during SSRI treatment. They attributed
this to a decrease in growth hormone secretion via "a
selective impairment of the somatotrophic axis by SSRIs
[[40], p. 699]." The authors called for more research and
warned clinicians to be wary of the potential for restricted
growth, given the increasing use of SSRIs with children.
Eventually, pharmacogenetics, "the increasingly impor-
tant branch of pharmacology that deals with the study of
genetic modifications of drug response [[26], p.266]," will
need to be considered in relation to pediatric psychophar-
macology. The field concerns individual differences in
drug response, and the study of "changes in phenotype
that occur as a child grows and Develops". This is an
emerging discipline: "pediatric or developmental pharma-
cogenetics is essentially at a neonatal stage [[22], p.777]
[see also [4,41]]."
5. Drugs are successful at treating psychiatric disorders
Psychotropics are only one of several treatments available
for psychiatric disorders in children and adolescents.
Obsessive-compulsive disorder (OCD) is a useful exam-
ple of a disorder usually treated with CBT and psychotrop-
ics, rather than psychotropics alone. OCD involves
compulsive behavior, such as "checking, washing, repeat-
ing, touching and straightening" [[42], p. 51]. Although
the phenomenology of OCD is the same, differences exist
in children and adolescents when compared to adults on
the gender distribution, comorbidity, genetic contribu-
tion, and development of OCD [42]. Prevalence estimates
vary from 0.2 percent to 1.2 percent in clinic settings to 1
to 4 percent in community settings. Shafran notes it is dif-
ficult for young people to verbalize their compulsions;
they "will often say that the compulsion is driven by a
sense that 'it doesn't feel right' unless such compulsive
behavior has been completed [[42], p. 51]." Since OCD is
comorbid with other disorders, diagnosis of OCD in chil-
dren is difficult. OCD can be confused with anxiety disor-
ders, again highlighting the importance of diagnostic
precision in DSM. There lacks a reliable and valid "gold
standard" assessment instrument, although semi-struc-
tured interviews are available.
In CBT, the goal is usually to expose the child to the feared
stimulus gradually, which blocks the negative reinforce-
ment effect of the compulsive behaviors (called exposure
and response prevention, or E/RP). CBT can help the
"patient make rapid and difficult behavior changes over
short time intervals [[6], p.16]." The cognitive component
of the therapy involves the development of a psychologi-
cal "tool kit" to help improve their "sense of personal effi-
cacy, predictability, controllability, and self-attributed
likelihood of a positive outcome with E/RP tasks" [[6], p.
9]. The compulsive behaviors can be terminated through
a process of extinction (by removing positive reinforce-
ment of the behaviors) and modeling:
"Modeling–whether overt (the child understands that
the therapist is demonstrating more appropriate or
adaptive coping behaviors) or covert (the therapist
informally models a behavior)– may help improve
compliance with in-session E/RP and generalization
to between-session E/RP homework [[7], p. 10]."
In contrast to depression, CBT alone, especially for
younger patients, or "CBT + medication" is the standard
initial treatment [see [43]]. CBT is an empirically sup-
ported treatment, which March et al. [6] argue has proven
more successful than insight-oriented psychotherapy. ThePage 6 of 10
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the disorder. OCD is characterized by intrusive thoughts,
which the patient appraises "as indicating responsibility
for harm or its prevention" [[42], p. 52]. This responsibil-
ity drives patients to take "corrective action" in the form
of the repetitive behaviors. A large literature supports the
efficacy of CBT for treatment of OCD in adults, and a
smaller literature supports it for children. SSRIs have also
shown effectiveness and are permitted for use in children
(unlike for depression) [42]. In a randomized, controlled
trial comparing CBT with clomipramine, the mean
improvement was higher at 60 percent in the CBT group
than in the clomipramine group at 33 percent [44]. Alter-
native treatments can therefore be used successfully along-
side psychotropics. Some argue CBT combined with SSRIs
is the most optimal strategy [6,27]. However, a recent Brit-
ish trial found that "the addition of CBT adds little to spe-
cialist active clinical care in conjunction with an SSRI in
the short term", at 28 weeks, despite the fact that CBT is
recommended as a treatment of choice by the National
Institute for Health and Clinical Excellence (NICE) [45].
In primary care settings, medication will usually be
favored and detract from nonpharmacological interven-
tions [17,45]. Parent training is another example of a non-
pharmacological intervention that can help treat and
prevent conduct disorders [46]. It is interesting that many
nonpharmacologic treatments are not covered by insur-
ance–even when they are cheaper and would perhaps be
more effective than psychotropics. The dramatic rise in
prescriptions has alarmed several commentators [notably
[1,18]]. In reality, the prescription of psychotropic drugs
is multi-determined. Prescription trends are influenced by
societal factors and pressures: regulatory guidelines and
the law, local policies, professional guidelines, clinicians'
own theoretical orientation, culture, parents, family val-
ues, schools, and the media [1-4,13,17,43,47,48]. In the
next section, we use the example of ADHD to illustrate
how multiple, social factors can influence psychotropic
prescription trends.
Validity of ADHD as a diagnosis
Another set of concerns about the prescribing of psycho-
tropics in children and young people is about the validity
of the diagnosis itself. Although ADHD, oppositional
defiant disorder, and conduct disorder have been vali-
dated, ADHD remains a controversial disorder. Concern
exists that "elevated but still developmentally normal lev-
els of motor activity, impulsiveness, or inattention" traits
of childhood could be inappropriately interpreted as
ADHD [5]. ADHD symptoms could mask other disorders,
such as mood disorders or cognitive impairments. Some
argue that Ritalin is prescribed for cosmetic reasons. Cos-
metic psychopharmacology refers to "pharmacologically
improving the brain functioning of healthy, normal indi-
viduals [[49], p. 113]." Social pressure means that "pass-
ing exams becomes ever more important to gain a
satisfactory job, and pass rates in school exit exams con-
tinue to rise year on year [[1], p. 1465]." MPH will main-
tain self-administration in laboratory animals, because it
increases dopaminergic activity in the same reward path-
way as cocaine and amphetamine. Children may be
encouraged to buy or sell Ritalin. Adolescents with ADHD
are already more likely to abuse other substances (e.g.,
nicotine), making them a high risk group because "college
years are a time of psychoactive drug use [[50], p. 142]."
In their sample, Babcock and Byrne [50] found that 16.6
percent of subjects reported taking Ritalin for fun, 16 per-
cent had snorted the drug, and 35.7 percent knew stu-
dents at the college from whom they could buy Ritalin
[see also [13]]. Students may be "pulling all nighters,"
indicating a form of self-administered cosmetic psychop-
harmacology (enhancement of brain functioning without
medical need). The authors concluded the abuse potential
of MPH should be considered when prescriptions are
made and MPH abuse "must be viewed as a public health
problem [[50] , p. 145]." Parents, wanting to give their
child the best start in life, report they feel justified in treat-
ing their children with Ritalin [48]. Indeed, the number of
prescriptions written for Ritalin far outweighs the esti-
mated prevalence of ADHD, suggesting that cosmetic use
is occurring [4]. This does not mean that cosmetic use
exists purely beyond full treatment of children with
ADHD. Under-treatment of ADHD can occur at the same
time as over-treatment, "as some children with ADHD
may not be adequately treated while others who do not
have ADHD are treated [[4], p.6] [[13], p. 64]." Indeed,
there is a possibility that "unmedicated children or ado-
lescents with ADHD may be more likely to "self-medi-
cate" by seeking out alcohol or illegal psychotropic agents
[[13], p. 67]." Mood disorders in younger children, partic-
ularly younger than six [2]. Treatment is usually focused
on controlling symptoms, rather than declaring a categor-
ical mood disorder, such as depression.
Addressing the absence of research
To address shortcomings in the research literature, the
National Institute of Mental Health funded a multi-site
trial, the Preschoolers with ADHD Treatment Study
(PATS). Given the 1.7 to 3.1-fold increase in MPH use
between 1991 and 1995 reported by Zito et al. [3], the
PATS study was launched in 2001 to address growing
safety and efficacy concerns. PATS took place over six sites.
Using strict criteria, eligible children shown to have
ADHD and able to tolerate treatment were randomized to
one of five conditions that differed by dose and, crucially,
a placebo condition. Following the study, all children
were eligible for ten months of treatment. This addressed
ethical concerns about withholding potentially beneficial
treatment, while also providing "systematic information
regarding the safety and relative long-term effectiveness ofPage 7 of 10
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interest was changes on parent and teacher rating scales–
validated and clearly defined measures of ADHD-related
behavioral functioning. The study was one of the first to
show an advantage of low MPH doses over placebo in the
classroom setting [47]. The dose-response relationship
was smaller in school-age children on the same medica-
tion, showing that differences do indeed exist between
pre-schoolers and school-age children which clinicians
need to consider. The study also showed the existence of
some side effects, however. Compared to the placebo con-
dition, MPH-treated children were more likely to show
decreased appetite and trouble sleeping throughout the
study, as well as weight loss at the beginning of the study.
In total, eleven percent of children enrolled in the study
had their participation ended because of intolerable
adverse events [52,53]. Swanson et al. found that treat-
ment slowed children's growth rate about 20 percent less
than expected for their height, with reductions of around
50 percent for weight after one year of continuous treat-
ment. Although these observations need to be balanced
against the risks of untreated ADHD, Wigal et al. con-
cluded "those preschoolers with ADHD on MPH treat-
ment still need to be carefully monitored [[53], p. 1302]."
The PATS study is a welcome addition to the literature on
psychotropic treatment of youth.
Three research priorities for the next decade
Three areas of research are likely to feature prominently
over the next decade. The first is the relationship between
psychotropics and stress. A complex relationship exists
among depression, stress, and stress hormones. The
hypothalamic-pituitary-adrenal axis (HPA axis) regulates
production of the stress hormone cortisol. In depression,
levels of cortisol are markedly elevated, and this may lead
to hippocampal damage. It is interesting that stress can
inhibit hippocampal neurogenesis, but SSRIs can induce
neurogenesis [19]. In rats, dentate granule cells in the hip-
pocampus increase by 70 percent after three weeks of
fluoxetine. Production of these cells can be suppressed by
stress or cortisol. Longitudinal studies of cortisol and hip-
pocampal volumes, comparing children treated with
SSRIs and controls, will be particularly informative. The
importance of life events as triggers of depression under-
scores the need to consider stress in more detail [31].
Second, a need exists for more research into the cosmetic
use of psychotropics by young people or parents of
younger children. As mentioned above, parents may seek
to capitalize on the side effects of psychotropics for
improving the educational attainment of their children
[48]. At the extreme, reports exist of Ritalin abuse by ado-
lescents who want to experience increased levels of con-
centration or the "high" associated with the drug [50].
Although Ritalin is similar to cocaine in terms of its
dopamine release mechanism, the clearance rate is much
slower, which may explain why it is not abused more [see,
[23]]. Sutcliffe and Wong [1] argue that practitioners need
to remain wary of both industry and societal pressures to
prescribe psychotropics when other options are available.
Finally, research into the diagnostic validity of psycholog-
ical disorders in children is likely to continue. The forth-
coming DSM-V will attempt to address the problems
associated with construct overlap, multiple diagnoses,
and overlapping symptoms, which have hampered
attempts to adequately describe and treat specific disor-
ders. Comorbidity of mood, substance, and personality
disorders may reflect a real tendency for children's symp-
toms to co-occur or to reflect the limitations of the current
scheme to differentiate adequately among distinct disor-
ders. An alternative scheme has been proposed which
addresses this problem:
"The factor connecting the unipolar mood and anxiety
disorders was labeled internalization, to describe the
propensity to express distress inwards that unites these
disorders. The factor connecting the substance use and
antisocial behavior disorders was labeled externaliza-
tion, to describe the propensity to express distress out-
wards that unites these disorders. Importantly,
internalization and externalization are conceived as
separate dimensions, as opposed to opposite ends of
the same dimension [[54], p. 1248]."
The tendency of "internalizing" and "externalizing" disor-
ders to co-vary is worth studying in its own right, rather
than being treated as a diagnostic problem per se [38,54].
According to Krueger et al. [[54], p. 1257], "SSRIs may be
better viewed as treatments for the core, shared tempera-
mental component of the internalizing disorders".
Comorbidity is the rule, rather than the exception, in
child and adolescent psychiatric disorders. For example,
ADHD frequently overlaps with internalizing and exter-
nalizing disorders [55]. Attempting to study disorders in
isolation by conducting research on "pure" cases could
limit the applied benefits of research. Efficacy trials are
usually conducted on healthy adults of a limited age
range. The typical "linear model" (from efficacy studies to
effectiveness studies, dissemination, and implementa-
tion) may not be appropriate. In real-world clinical set-
tings, patients may have multiple problems, which brings
"a large array of new, confounding variables [[19], p.
967]." Hyman argues that the exclusion criteria for many
studies mean we have limited information on young peo-
ple most at risk. Studies usually exclude patients at risk of
suicide, meaning little information exists on how to man-
age and treat suicidal adolescent patients.Page 8 of 10
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We can expect to see the development of child and adoles-
cent versions of questionnaires and interviews, the devel-
opment of normative data for childhood mental
disorders, and safety/efficacy studies. These studies will
need to be conducted on specific age groups, specific dis-
orders, and with specific treatments. Prescribed psycho-
tropic medications are now high on the research agenda.
Recent news coverage, as well as changes in both clinical
practice standards and drug product labelling, have
extended researchers' concerns into the wider public [see
[3]]. The traditional reluctance to enrol children in clinical
trials of psychotropics, such as MPH or SSRIs, has had the
effect of increasing, not decreasing, their vulnerability as a
special population. Continued discussion about the ethi-
cal challenges of research [17,24,28,48,49] and the devel-
opment of well-designed, placebo-controlled trials, have
begun to change this situation. For the first time, we can
begin to record and measure, rather than assume, the
impact of prescribed psychotropics on children and ado-
lescents. Few would disagree with Spetie and Arnold
[[17], p. 21] that "children and adolescents have the right
to treatment based on accurate, age-appropriate data."
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